Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Editas Medicine regains full global rights to ocular medicines » 16:04
08/06/20
08/06
16:04
08/06/20
16:04
EDIT

Editas Medicine

$36.72 /

+4.36 (+13.47%)

, ABBV

AbbVie

$92.61 /

-0.62 (-0.67%)

Editas Medicine (EDIT)…

Editas Medicine (EDIT) announced it has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber congenital amaurosis 10, which were previously shared within a strategic research and development alliance with Allergan, which has since been acquired by AbbVie (ABBV). Editas Medicine and AbbVie have terminated the original agreement and entered into a new agreement.

ShowHide Related Items >><<
EDIT Editas Medicine
$36.72 /

+4.36 (+13.47%)

ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

EDIT Editas Medicine
$36.72 /

+4.36 (+13.47%)

06/18/20 Truist
Editas Medicine initiated with a Buy at SunTrust
02/27/20 Raymond James
Editas Medicine price target lowered to $41 from $44 at Raymond James
02/21/20 Wells Fargo
Editas Medicine initiated with an Equal Weight at Wells Fargo
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

08/05/20 Benchmark
Voyager 'break up' with AbbVie has no impact on valuation, says Benchmark
07/31/20 Piper Sandler
Piper reiterates $110 target on AbbVie after 'impressive beat'
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
EDIT Editas Medicine
$36.72 /

+4.36 (+13.47%)

ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

  • 24
    Jun
EDIT Editas Medicine
$36.72 /

+4.36 (+13.47%)

ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

EDIT Editas Medicine
$36.72 /

+4.36 (+13.47%)

ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

ABBV AbbVie
$92.61 /

-0.62 (-0.67%)

Wednesday
Recommendations
Voyager 'break up' with AbbVie has no impact on valuation, says Benchmark » 07:29
08/05/20
08/05
07:29
08/05/20
07:29
VYGR

Voyager Therapeutics

$10.35 /

-1.01 (-8.89%)

, ABBV

AbbVie

$94.28 /

-1.68 (-1.75%)

After Voyager (VYGR)…

After Voyager (VYGR) reported the termination of its tau and alpha-synuclein vectorized antibody agreement with AbbVie (ABBV), Benchmark analyst Aydin Huseynov said the end of this preclinical-stage collaboration has no impact on his valuation for Voyager and he sees it as attributable to AbbVie reallocating resources and potentially shifting focus to later-stage deals. Voyager can potentially out-license this tau/alpha-synuclein technology to others and he suspects management is already in such talks, added Huseynov, who has a Buy rating and $20 price target on Voyager shares.

ShowHide Related Items >><<
VYGR Voyager Therapeutics
$10.35 /

-1.01 (-8.89%)

ABBV AbbVie
$94.28 /

-1.68 (-1.75%)

VYGR Voyager Therapeutics
$10.35 /

-1.01 (-8.89%)

08/04/20 H.C. Wainwright
Voyager Therapeutics price target lowered to $14 from $18 at H.C. Wainwright
03/30/20 Nomura Instinet
Voyager Therapeutics price target lowered to $16 from $37 at Nomura Instinet
03/19/20
Fly Intel: Top five analyst initiations
03/19/20 Benchmark
Benchmark starts Voyager Therapeutics at Buy with $18 price target
ABBV AbbVie
$94.28 /

-1.68 (-1.75%)

07/31/20 Piper Sandler
Piper reiterates $110 target on AbbVie after 'impressive beat'
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
VYGR Voyager Therapeutics
$10.35 /

-1.01 (-8.89%)

ABBV AbbVie
$94.28 /

-1.68 (-1.75%)

ABBV AbbVie
$94.28 /

-1.68 (-1.75%)

ABBV AbbVie
$94.28 /

-1.68 (-1.75%)

ABBV AbbVie
$94.28 /

-1.68 (-1.75%)

Monday
Hot Stocks
Voyager provides update on AbbVie vectorized antibody collaborations » 16:06
08/03/20
08/03
16:06
08/03/20
16:06
VYGR

Voyager Therapeutics

$11.31 /

+0.26 (+2.35%)

, ABBV

AbbVie

$95.85 /

+0.965 (+1.02%)

Voyager Therapeutics…

Voyager Therapeutics (VYGR) announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie (ABBV). Voyager retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations. "Our efforts to harness AAV-based gene therapy to produce antibodies directly in the brain and overcome major limitations with delivery of current biologics across the blood-brain barrier have been highly productive," said Omar Khwaja, M.D., Ph.D., Chief Medical Officer and Head of R&D at Voyager. "Through the tau and alpha-synuclein collaborations, we believe we have made considerable progress against targets for neurodegenerative diseases with this novel approach, reinforcing our enthusiasm for its potential to deliver therapeutically efficacious levels of biologics to the brain and central nervous system. We believe our continued work on discovery and design of novel AAV capsids with substantially improved blood-brain barrier penetrance will also considerably broaden the potential of AAV-based gene therapy, including vectorized antibodies or other biologics, for the treatment of severe neurological diseases." The tau and alpha-synuclein research collaborations were formed in 2018 and 2019, respectively. Under the terms of the collaboration agreements, Voyager received upfront payments to perform research and preclinical development of vectorized antibodies directed against tau and alpha-synuclein. With the conclusion of the collaborations, Voyager has regained full clinical development and commercialization rights to certain product candidates developed within the context of the collaboration for the tau program. Voyager is free to pursue vectorized antibody programs for tau and alpha-synuclein alone or in collaboration with another partner. Voyager does not anticipate any changes to its cash runway guidance due to the termination of the agreements. As of March 31, 2020, the Company had cash, cash equivalents and marketable debt securities of $250.9 million, which, along with amounts expected to be received for reimbursement of development costs from Neurocrine Biosciences, is expected to be sufficient to meet Voyager's projected operating expenses and capital expenditure requirements into mid-2022.

ShowHide Related Items >><<
VYGR Voyager Therapeutics
$11.31 /

+0.26 (+2.35%)

ABBV AbbVie
$95.85 /

+0.965 (+1.02%)

VYGR Voyager Therapeutics
$11.31 /

+0.26 (+2.35%)

03/30/20 Nomura Instinet
Voyager Therapeutics price target lowered to $16 from $37 at Nomura Instinet
03/19/20
Fly Intel: Top five analyst initiations
03/19/20 Benchmark
Benchmark starts Voyager Therapeutics at Buy with $18 price target
03/19/20 Benchmark
Voyager Therapeutics initiated with a Buy at Benchmark
ABBV AbbVie
$95.85 /

+0.965 (+1.02%)

07/31/20 Piper Sandler
Piper reiterates $110 target on AbbVie after 'impressive beat'
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
VYGR Voyager Therapeutics
$11.31 /

+0.26 (+2.35%)

ABBV AbbVie
$95.85 /

+0.965 (+1.02%)

ABBV AbbVie
$95.85 /

+0.965 (+1.02%)

ABBV AbbVie
$95.85 /

+0.965 (+1.02%)

ABBV AbbVie
$95.85 /

+0.965 (+1.02%)

Hot Stocks
Members of COVID R&D Alliance enroll first patients in I-SPY COVID Trial » 07:35
08/03/20
08/03
07:35
08/03/20
07:35
ABBV

AbbVie

$94.89 /

-1.115 (-1.16%)

, AMGN

Amgen

$244.61 /

-1.37 (-0.56%)

, TAK

Takeda Pharmaceutical

$18.21 /

+0.03 (+0.17%)

Members of the COVID…

Members of the COVID R&D Alliance, AbbVie (ABBV), Amgen (AMGN), and Takeda Pharmaceutical Co. (TAK), announced the first patients enrolled in the I-SPY COVID Trial clinical trial. The I-SPY COVID Trial will evaluate the efficacy of cenicriviroc, a chemokine (CCR2 and CCR5) dual-receptor antagonist, Otezla , a PDE4 inhibitor, and Firazyr, a bradykinin B2 receptor antagonist in severely ill, hospitalized COVID-19 patients who require high-flow oxygen. The I-SPY COVID Trial utilizes Quantum Leap Healthcare collaborative's adaptive platform trial design, which is intended to increase trial efficiency by minimizing the number of participants and time required to evaluate potential treatments.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$18.21 /

+0.03 (+0.17%)

AMGN Amgen
$244.61 /

-1.37 (-0.56%)

ABBV AbbVie
$94.89 /

-1.115 (-1.16%)

ABBV AbbVie
$94.89 /

-1.115 (-1.16%)

07/31/20 Piper Sandler
Piper reiterates $110 target on AbbVie after 'impressive beat'
07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
AMGN Amgen
$244.61 /

-1.37 (-0.56%)

07/29/20 SVB Leerink
Amgen price target raised to $261 from $253 at SVB Leerink
07/29/20 Wells Fargo
Amgen price target raised to $247 from $237 at Wells Fargo
07/29/20 RBC Capital
Amgen price target lowered to $223 from $236 at RBC Capital
TAK Takeda Pharmaceutical
$18.21 /

+0.03 (+0.17%)

06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
06/17/20 Oppenheimer
Takeda deal expands Neurocrine's pipeline into psychiatry, says Oppenheimer
04/20/20 SVB Leerink
Ascendis Pharma price target raised to $170 from $152 at SVB Leerink
03/25/20 Piper Sandler
Piper Sandler backs Overweight on 'well capitalized' Exelixis
AMGN Amgen
$244.61 /

-1.37 (-0.56%)

ABBV AbbVie
$94.89 /

-1.115 (-1.16%)

TAK Takeda Pharmaceutical
$18.21 /

+0.03 (+0.17%)

AMGN Amgen
$244.61 /

-1.37 (-0.56%)

ABBV AbbVie
$94.89 /

-1.115 (-1.16%)

AMGN Amgen
$244.61 /

-1.37 (-0.56%)

ABBV AbbVie
$94.89 /

-1.115 (-1.16%)

TAK Takeda Pharmaceutical
$18.21 /

+0.03 (+0.17%)

AMGN Amgen
$244.61 /

-1.37 (-0.56%)

ABBV AbbVie
$94.89 /

-1.115 (-1.16%)

Over a week ago
Recommendations
Piper reiterates $110 target on AbbVie after 'impressive beat' » 14:25
07/31/20
07/31
14:25
07/31/20
14:25
ABBV

AbbVie

$94.19 /

-1.81 (-1.89%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond reiterates an Overweight rating on AbbVie with a $110 price target citing this morning's "impressive beat." The quarter is a continuation of the operational theme that COVID-19 impact on biopharma stocks has been less than feared, Raymond tells investors in a research note. The analyst says that with three immunology drivers, Humira, Skyrizi and Rinvoq, all outperforming, Allergan's aesthetics business recovering far "faster than anyone anticipated," and an "up-and-coming but still underappreciated migraine franchise," he likes the way the business is headed. AbbVie is poised for double digit earnings growth "easily into 2022," says Raymond, who remains a buyer of the stock.

ShowHide Related Items >><<
ABBV AbbVie
$94.19 /

-1.81 (-1.89%)

ABBV AbbVie
$94.19 /

-1.81 (-1.89%)

07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
07/07/20 Truist
Evolus price target lowered to $6 from $12 at SunTrust
ABBV AbbVie
$94.19 /

-1.81 (-1.89%)

ABBV AbbVie
$94.19 /

-1.81 (-1.89%)

ABBV AbbVie
$94.19 /

-1.81 (-1.89%)

ABBV AbbVie
$94.19 /

-1.81 (-1.89%)

Earnings
AbbVie sees FY20 revenue approximately $45.5B, consensus $45.47B  09:36
07/31/20
07/31
09:36
07/31/20
09:36
ABBV

AbbVie

$96.00 /

-0.955 (-0.98%)

 
ShowHide Related Items >><<
ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
07/07/20 Truist
Evolus price target lowered to $6 from $12 at SunTrust
ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

Earnings
AbbVie sees Q3 adjusted EPS $2.73-$2.77, consensus $2.75 » 09:35
07/31/20
07/31
09:35
07/31/20
09:35
ABBV

AbbVie

$96.00 /

-0.955 (-0.98%)

Sees Q3 revenue…

Sees Q3 revenue approximately $12.8B, consensus $12.65B. Guidance taken from Q2 earnings conference call.

ShowHide Related Items >><<
ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
07/07/20 Truist
Evolus price target lowered to $6 from $12 at SunTrust
ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

Hot Stocks
AbbVie says 'confident' in strong underlying demand for combined company » 09:16
07/31/20
07/31
09:16
07/31/20
09:16
ABBV

AbbVie

$96.00 /

-0.955 (-0.98%)

Says integration with…

Says integration with Allergan has been "relatively seamless." Seeing "very encouraging trends" for Rinvoq. Says making "excellent progress" with immunology pipeline. Sees further operating margin expansion over next several years. Continues to see "good momentum" across portfolio. Comments taken from Q2 earnings conference call.

ShowHide Related Items >><<
ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
07/07/20 Truist
Evolus price target lowered to $6 from $12 at SunTrust
ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

On The Fly
Fly Intel: Pre-market Movers » 08:54
07/31/20
07/31
08:54
07/31/20
08:54
MDRX

Allscripts

$7.60 /

+0.175 (+2.36%)

, MRK

Merck

$79.05 /

-0.28 (-0.35%)

, CHTR

Charter

$563.79 /

-2.47 (-0.44%)

, ABBV

AbbVie

$96.00 /

-0.955 (-0.98%)

, LHX

L3Harris Technologies

$173.09 /

+0.38 (+0.22%)

, CHD

Church & Dwight

$90.09 /

+0.72 (+0.81%)

, PINS

Pinterest

$25.15 /

+0.2 (+0.80%)

, UA

Under Armour

$10.20 /

-0.14 (-1.35%)

, UAA

Under Armour

$11.47 /

-0.15 (-1.29%)

, FB

Facebook

$234.63 /

+1.31 (+0.56%)

, AAPL

Apple

$385.14 /

+4.91 (+1.29%)

, AMZN

Amazon.com

$3,050.97 /

+17.7 (+0.58%)

, CVX

Chevron

$86.29 /

-3.775 (-4.19%)

, XOM

Exxon Mobil

$41.88 /

-2.18 (-4.95%)

, EXPE

Expedia

$84.94 /

-0.36 (-0.42%)

, SHAK

Shake Shack

$55.47 /

+0.63 (+1.15%)

, GILD

Gilead

$72.30 /

-0.74 (-1.01%)

, TEAM

Atlassian

$188.01 /

+0.86 (+0.46%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
XOM Exxon Mobil
$41.88 /

-2.18 (-4.95%)

UAA Under Armour
$11.47 /

-0.15 (-1.29%)

UA Under Armour
$10.20 /

-0.14 (-1.35%)

TEAM Atlassian
$188.01 /

+0.86 (+0.46%)

SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

PINS Pinterest
$25.15 /

+0.2 (+0.80%)

MRK Merck
$79.05 /

-0.28 (-0.35%)

MDRX Allscripts
$7.60 /

+0.175 (+2.36%)

LHX L3Harris Technologies
$173.09 /

+0.38 (+0.22%)

GILD Gilead
$72.30 /

-0.74 (-1.01%)

FB Facebook
$234.63 /

+1.31 (+0.56%)

EXPE Expedia
$84.94 /

-0.36 (-0.42%)

CVX Chevron
$86.29 /

-3.775 (-4.19%)

CHTR Charter
$563.79 /

-2.47 (-0.44%)

CHD Church & Dwight
$90.09 /

+0.72 (+0.81%)

AMZN Amazon.com
$3,050.97 /

+17.7 (+0.58%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

MDRX Allscripts
$7.60 /

+0.175 (+2.36%)

07/21/20 Goldman Sachs
Allscripts downgraded to Sell from Neutral at Goldman Sachs
06/11/20 Deutsche Bank
Allscripts price target lowered to $9 from $11 at Deutsche Bank
04/22/20 Jefferies
Allscripts downgraded to Hold due to pressure on customers at Jefferies
04/22/20 Jefferies
Allscripts downgraded to Hold from Buy at Jefferies
MRK Merck
$79.05 /

-0.28 (-0.35%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
CHTR Charter
$563.79 /

-2.47 (-0.44%)

07/22/20 Guggenheim
Charter price target raised to $620 from $570 at Guggenheim
07/22/20 Deutsche Bank
Charter price target raised to $650 from $600 at Deutsche Bank
07/10/20
Fly Intel: Top five analyst upgrades
07/10/20 Nomura Instinet
Charter upgraded to Buy from Neutral at Nomura Instinet
ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/07/20 Truist
Evolus price target lowered to $6 from $12 at SunTrust
LHX L3Harris Technologies
$173.09 /

+0.38 (+0.22%)

07/20/20 Credit Suisse
L3Harris Technologies price target lowered to $205 from $226 at Credit Suisse
06/26/20 Cowen
L3Harris Technologies selloff appears overdone, says Cowen
05/22/20 Jefferies
Jefferies adds six names to Franchise Picks list, including BioMarin and TJX
05/20/20 RBC Capital
RBC starts 'best-in-class' L3Harris Technologies at Outperform
CHD Church & Dwight
$90.09 /

+0.72 (+0.81%)

07/24/20 Oppenheimer
Church & Dwight price target raised to $100 from $88 at Oppenheimer
07/16/20 JPMorgan
Church & Dwight price target raised to $74 from $68 at JPMorgan
07/15/20 Argus
Church & Dwight initiated with a Buy at Argus
07/15/20 Argus
Church & Dwight initiated with a Buy at Argus
PINS Pinterest
$25.15 /

+0.2 (+0.80%)

07/21/20 Deutsche Bank
Pinterest price target raised to $29 from $27 at Deutsche Bank
07/20/20 Goldman Sachs
Pinterest price target raised to $26 from $17 at Goldman Sachs
07/15/20 JPMorgan
Pinterest price target raised to $26 from $17 at JPMorgan
07/13/20 Barclays
Pinterest price target raised to $26 from $20 at Barclays
UA Under Armour
$10.20 /

-0.14 (-1.35%)

07/28/20 Jefferies
Under Armour 'inquiry matters, but it doesn't matter,' says Jefferies
07/23/20 Jefferies
Jefferies 'wouldn't chase' Nike shares near all-time highs
07/10/20 Morgan Stanley
Under Armour appears to be taking 'prudent look' at costs, says Morgan Stanley
05/12/20 Barclays
Under Armour price target lowered to $9 from $10 at Barclays
UAA Under Armour
$11.47 /

-0.15 (-1.29%)

07/24/20 Deutsche Bank
Under Armour named short-term buy idea at Deutsche Bank
07/21/20 BTIG
BTIG sees signs of distress at Under Armour, keeps $5 price target
FB Facebook
$234.63 /

+1.31 (+0.56%)

07/31/20 Wedbush
Facebook price target raised to $300 from $250 at Wedbush
07/31/20 RBC Capital
Facebook price target raised to $320 from $271 at RBC Capital
07/31/20 Raymond James
Facebook price target raised to $280 from $240 at Raymond James
07/31/20 Jefferies
Facebook price target raised to $300 from $285 at Jefferies
AAPL Apple
$385.14 /

+4.91 (+1.29%)

07/31/20 Loop Capital
Apple price target raised to $376 from $330 at Loop Capital
07/31/20 DA Davidson
Apple price target raised to $480 from $355 at DA Davidson
07/31/20 Jefferies
Apple price target raised to $465 from $405 at Jefferies
AMZN Amazon.com
$3,050.97 /

+17.7 (+0.58%)

07/31/20 Wedbush
Amazon.com price target raised to $3,700 from $3,500 at Wedbush
07/31/20 Truist
Amazon.com price target raised to $3,600 from $3,400 at SunTrust
07/31/20 MKM Partners
Amazon.com price target raised to $3,650 from $3,350 at MKM Partners
07/31/20 Needham
Amazon.com price target raised to $3,700 from $3,200 at Needham
CVX Chevron
$86.29 /

-3.775 (-4.19%)

07/23/20 Truist
SunTrust starts Chevron with Buy rating, $120 price target
07/23/20 Truist
Chevron initiated with a Buy at SunTrust
07/22/20 Argus
Noble Energy downgraded to Sell from Hold at Argus
07/21/20 Morgan Stanley
Chevron discipline paid off with deal for Noble, says Morgan Stanley
XOM Exxon Mobil
$41.88 /

-2.18 (-4.95%)

07/23/20 Truist
SunTrust starts Exxon with Hold rating, $41 price target
07/23/20 Truist
Exxon Mobil initiated with a Hold at SunTrust
06/09/20 Standpoint Research
Exxon Mobil downgraded to Hold from Buy at Standpoint Research
06/09/20 JPMorgan
Exxon Mobil price target raised to $51 from $44 at JPMorgan
EXPE Expedia
$84.94 /

-0.36 (-0.42%)

07/31/20 RBC Capital
Expedia price target lowered to $93 from $105 at RBC Capital
07/29/20 Jefferies
Booking Holdings price target raised to $1,600 from $1,300 at Jefferies
07/20/20 Goldman Sachs
Expedia price target raised to $65 from $60 at Goldman Sachs
07/15/20 Mizuho
Expedia price target raised to $85 from $80 at Mizuho
SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

07/31/20 Jefferies
Shake Shack price target raised to $50 from $45 at Jefferies
07/10/20 MKM Partners
Shake Shack price target lowered to $54 from $59 at MKM Partners
07/08/20 MKM Partners
Shake Shack's comps recovery continues at 'tempered pace', says MKM Partners
06/24/20 JPMorgan
Shake Shack price target raised to $51 from $47 at JPMorgan
GILD Gilead
$72.30 /

-0.74 (-1.01%)

07/31/20 Wells Fargo
Gilead price target lowered to $76 from $87 at Wells Fargo
07/30/20 Piper Sandler
Gilead price target lowered to $85 from $90 at Piper Sandler
07/28/20 Piper Sandler
Piper Sandler lowers FY20, FY21 earnings forecasts for Gilead
07/20/20
Fly Intel: Top five analyst upgrades
TEAM Atlassian
$188.01 /

+0.86 (+0.46%)

07/20/20 Cleveland Research
Atlassian survey shows better than expected quarter, says Cleveland Research
07/20/20 Jefferies
Atlassian price target raised to $175 from $145 at Jefferies
07/14/20 Morgan Stanley
Atlassian price target raised to $200 from $173 at Morgan Stanley
07/01/20 KeyBanc
Atlassian price target raised to $201 from $163 at KeyBanc
XOM Exxon Mobil
$41.88 /

-2.18 (-4.95%)

UA Under Armour
$10.20 /

-0.14 (-1.35%)

TEAM Atlassian
$188.01 /

+0.86 (+0.46%)

SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

PINS Pinterest
$25.15 /

+0.2 (+0.80%)

MRK Merck
$79.05 /

-0.28 (-0.35%)

MDRX Allscripts
$7.60 /

+0.175 (+2.36%)

LHX L3Harris Technologies
$173.09 /

+0.38 (+0.22%)

GILD Gilead
$72.30 /

-0.74 (-1.01%)

FB Facebook
$234.63 /

+1.31 (+0.56%)

EXPE Expedia
$84.94 /

-0.36 (-0.42%)

CVX Chevron
$86.29 /

-3.775 (-4.19%)

CHTR Charter
$563.79 /

-2.47 (-0.44%)

CHD Church & Dwight
$90.09 /

+0.72 (+0.81%)

AMZN Amazon.com
$3,050.97 /

+17.7 (+0.58%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

  • 16
    Oct
XOM Exxon Mobil
$41.88 /

-2.18 (-4.95%)

UA Under Armour
$10.20 /

-0.14 (-1.35%)

TEAM Atlassian
$188.01 /

+0.86 (+0.46%)

SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

PINS Pinterest
$25.15 /

+0.2 (+0.80%)

MRK Merck
$79.05 /

-0.28 (-0.35%)

GILD Gilead
$72.30 /

-0.74 (-1.01%)

FB Facebook
$234.63 /

+1.31 (+0.56%)

EXPE Expedia
$84.94 /

-0.36 (-0.42%)

CVX Chevron
$86.29 /

-3.775 (-4.19%)

CHTR Charter
$563.79 /

-2.47 (-0.44%)

AMZN Amazon.com
$3,050.97 /

+17.7 (+0.58%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

XOM Exxon Mobil
$41.88 /

-2.18 (-4.95%)

UA Under Armour
$10.20 /

-0.14 (-1.35%)

TEAM Atlassian
$188.01 /

+0.86 (+0.46%)

SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

PINS Pinterest
$25.15 /

+0.2 (+0.80%)

MRK Merck
$79.05 /

-0.28 (-0.35%)

MDRX Allscripts
$7.60 /

+0.175 (+2.36%)

LHX L3Harris Technologies
$173.09 /

+0.38 (+0.22%)

GILD Gilead
$72.30 /

-0.74 (-1.01%)

FB Facebook
$234.63 /

+1.31 (+0.56%)

EXPE Expedia
$84.94 /

-0.36 (-0.42%)

CVX Chevron
$86.29 /

-3.775 (-4.19%)

CHTR Charter
$563.79 /

-2.47 (-0.44%)

CHD Church & Dwight
$90.09 /

+0.72 (+0.81%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

XOM Exxon Mobil
$41.88 /

-2.18 (-4.95%)

UAA Under Armour
$11.47 /

-0.15 (-1.29%)

UA Under Armour
$10.20 /

-0.14 (-1.35%)

TEAM Atlassian
$188.01 /

+0.86 (+0.46%)

SHAK Shake Shack
$55.47 /

+0.63 (+1.15%)

PINS Pinterest
$25.15 /

+0.2 (+0.80%)

MRK Merck
$79.05 /

-0.28 (-0.35%)

GILD Gilead
$72.30 /

-0.74 (-1.01%)

FB Facebook
$234.63 /

+1.31 (+0.56%)

EXPE Expedia
$84.94 /

-0.36 (-0.42%)

CVX Chevron
$86.29 /

-3.775 (-4.19%)

CHD Church & Dwight
$90.09 /

+0.72 (+0.81%)

AMZN Amazon.com
$3,050.97 /

+17.7 (+0.58%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

AAPL Apple
$385.14 /

+4.91 (+1.29%)

Hot Stocks
AbbVie CEO: Adverse COVID-19 impact on legacy AbbVie 'was less than expected' » 07:50
07/31/20
07/31
07:50
07/31/20
07:50
ABBV

AbbVie

$96.00 /

-0.955 (-0.98%)

"AbbVie delivered…

"AbbVie delivered another strong quarterly performance, ahead of our guidance. The adverse impact from COVID-19 on legacy AbbVie was less than expected, demonstrating the robustness and resiliency of our key brands, and new patient starts have stabilized and started to recover," said Richard Gonzalez, chairman and CEO, AbbVie. "The integration of Allergan is going well, with a strong recovery in the aesthetics portfolio and accretion ahead of expectations."

ShowHide Related Items >><<
ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

07/29/20 Piper Sandler
Piper says AbbVie's atogepant 'may yet emerge as best in class'
07/29/20 Piper Sandler
Biohaven migraine competitor shows constipation signal, says Piper Sandler
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
07/07/20 Truist
Evolus price target lowered to $6 from $12 at SunTrust
ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

ABBV AbbVie
$96.00 /

-0.955 (-0.98%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.